spacer spacer

spacer

News

NanoString Wins FDA Approval of Breast Cancer Diagnostic Test

2013-09-10

GPEC has been working closely with NanoString for the past three years on this FDA approval submission. The FDA approved Prosigna test is based on the breast cancer intrinsic subtype gene expression profiling (PAM50) research, a collaborative study between University of North Carolina, Washington University, University of Utah and GPEC.

More information can be found at:

View News Archive

spacer
spacer
spacer
Logo
spacer
spacer
Copyright © 2014 Genetic Pathology Evaluation Centre All Rights Reserved; Last modified June 18, 2014